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Abstract 1 
The difficulty in isolating and propagating functional primary cholangiocytes is 2 
a major limitation in studying biliary disorders and testing novel therapeutic 3 
agents. To overcome this problem, we have developed a platform for the 4 
differentiation of human Pluripotent Stem Cells (hPSCs) into functional 5 
cholangiocyte-like cells (CLCs). We have previously reported that our 26-day 6 
protocol closely recapitulates key stages of biliary development starting with 7 
the differentiation of hPSCs into endoderm and subsequently foregut 8 
progenitor cells, followed by the generation of hepatoblasts, cholangiocyte 9 
progenitors expressing early biliary markers and mature CLCs displaying 10 
cholangiocyte functionality. Compared to alternative protocols for biliary 11 
differentiation of hPSCs, our system does not require co-culture with other cell 12 
types and relies on chemically defined conditions up to and including the 13 
generation of cholangiocyte progenitors. A complex extracellular matrix is 14 
used for the maturation of CLCs, therefore experience in hPSC culture and 15 
3D organoid systems may be necessary for optimal results. Finally, the 16 
capacity of our platform for generating large amounts of disease-specific 17 
functional cholangiocytes will have broad applications for cholangiopathies, in 18 
disease modeling and for screening of therapeutic compounds. 19 
 20 
  21 
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INTRODUCTION 1 
 2 
Adult bile ducts consist of highly functional biliary epithelial cells1 which 3 
regulate bile homeostasis and modulate inflammatory responses. These cells 4 
are also known as cholangiocytes and represent the main cell type affected in 5 
cholangiopathies2,3; a diverse group of liver disorders including diseases such 6 
as Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Despite the 7 
growing importance of these diseases, research in biliary physiology and the 8 
development of new therapeutics have been hampered by the lack of robust 9 
platforms for disease modeling and high-throughput drug screening3,4. 10 
Although animal models exist, their capacity for fully reproducing human 11 
pathophysiology is limited5,6; while access to primary biliary tissue remains 12 
problematic prohibiting large scale experiments. Here, we describe a protocol 13 
for generating large quantities of CLCs from human hPSCs, which can be 14 
applied to model cholangiopathies in vitro and validate the effects of 15 
therapeutic compounds6. 16 
 17 
Development of the protocol 18 
The protocol for the generation of cholangiocyte-like cells7 was developed by 19 
recapitulating key stages of native bile duct development (Figure 1a). 20 
Cholangiocytes originate from hepatoblasts (HBs), a bipotent population of 21 
embryonic liver progenitor cells8, which can also differentiate into 22 
hepatocytes. Hepatoblasts surrounding the portal vein give rise to a 23 
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monolayer of immature cholangiocyte progenitor cells (the ductal plate)8, 1 
which undergoes a process of 3D remodeling and maturation resulting in 2 
functional bile ducts.  3 
The generation of bipotent HBs was based on our established methodology 4 
for producing hPSC-derived hepatocyte-like cells9. To achieve biliary 5 
commitment of HBs, we used physiological cues reported to control biliary 6 
specification such as Activin-A (a member of the TGFbeta superfamily)8,10 and 7 
Fibroblast Growth Factor (FGF) 1011. Screening a variety of growth factors, 8 
we also identified a requirement for Retinoic Acid7. The combined activation of 9 
these signaling pathways was sufficient to promote differentiation of HBs to 10 
cholangiocyte progenitors expressing early biliary markers including KRT19 11 
and SOX97. 12 
Maturation of native cholangiocytes happens in synchrony with 3D 13 
rearrangement of the ductal plate into tubular structures8. Most of the 14 
functional properties of the biliary epithelium are associated with absorption 15 
and secretion processes, which require a polarized epithelium forming a 16 
lumen and therefore cannot be accurately reproduced by cells organized in 17 
monolayer12,13. Consequently, for the final stage of our protocol promoting CP 18 
maturation to CLCs, we developed a 3D culture system, based on previous 19 
studies using matrigel and Epidermal Growth Factor (EGF)14,15 which promote 20 
spontaneous differentiation of hepatoblasts into cystic structures expressing 21 
early biliary markers, such as KRT1914,15. Prolonged culture of CPs under 22 
these conditions resulted in CLC organoids with a central lumen 23 
demonstrating characteristic functional properties, such as GGT activity7  24 
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 1 
Applications 2 
The mechanisms controlling development of the human biliary tree remain 3 
poorly understood. Indeed, developmental studies in humans is limited by 4 
minimal access to fetal tissue, while animal models fail to fully recapitulate the 5 
development of the human biliary tree or the phenotype of developmental 6 
disorders6. Our in vitro system could address some of these challenges, as it 7 
relies on a step-wise differentiation protocol which closely mimics embryonic 8 
bile duct development. Therefore, significant numbers of cells corresponding 9 
to different embryological stages can be easily generated, enabling 10 
mechanistic large scale studies in biliary specification or developmental 11 
disorders. Accordingly, we applied this methodology to interrogate the role of 12 
TGFβ and Notch signaling in biliary tubulogenesis and reproduce the 13 
phenotype of Alagille Syndrome in vitro7. The same principle could be used in 14 
future studies to explore a broad spectrum of pathways which could be 15 
involved in bile duct development and pathogenesis.  16 
CLCs also recapitulate many  physiological functions of cholangiocytes in vitro 17 
as well as their defects in the context of disease when using hPSCs derived 18 
from patients with cholangiopathies7. Consequently, CLCs could present an 19 
optimal platform for modeling biliary disease, validating therapeutic 20 
compounds and screening for novel treatment agents. We have already 21 
demonstrated proof-of-principle for the feasibility of this application by 22 
reproducing the effects of the drugs verapamil and octreotide in our culture 23 
system7 and using patient specific hiPSCs to identify a new application for the 24 
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experimental compound VX809 in the management of Cystic Fibrosis 1 
Cholangiopathy7. Importantly, the capacity of our system for generating 2 
significant numbers of CLCs7 combined with its compatibility with large scale 3 
experiment formats (24 and 48 well plates)7 could set the foundation for the 4 
development of high-throughput drug screening platforms for 5 
cholangiopathies in the future using patient-derived CLCs. 6 
Comparison with other methods 7 
Primary cholangiocyte isolation has been reported16–18. However, these 8 
methodologies are technically challenging, only support short term growth 9 
with limited expansion and generate limited numbers of cells, all of which are 10 
not compatible with large scale experiments16–18. Furthermore, primary 11 
cholangiocytes cultured in monolayer systems have not been shown to 12 
maintain their functional properties16–18.  13 
Two other protocols have been described for generating biliary epithelium 14 
from hPSCs19,20. The method by Dianat et al. results in cells with a 15 
transcriptional signature7,20 compatible with a sub-population of 16 
cholangiocytes located in the canals of Hering known as small 17 
cholangiocytes21. Therefore, this approach is optimized for studies on small 18 
cholangiocytes and complements our protocol which is aimed towards the 19 
production of large cholangiocytes. The method by Ogawa et al. generates 20 
cholangiocyte organoids expressing mature markers and demonstrating 21 
biliary functionality; however, biliary specification is based in a co-culture 22 
system with mouse OP9 cells13. Although a mixed culture system may 23 
recapitulate more closely the native niche of hepatoblasts/cholangiocytes, it is 24 
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technically more challenging and presents several limitations. Indeed, OP9 1 
cells are derived from bone marrow and are known to promote hematopoietic 2 
differentiation of ESCs by secreting factors such as M-CSF. This poses 3 
significant limitations for mechanistic studies in biliary specification and early 4 
biliary development since unknown secreted factors could interfere with 5 
experimental outcomes. Furthermore, the heterogeneity of the cell population 6 
in a co-culture system renders –omic studies, such as genome wide analyses 7 
more challenging. Consequently, the platform by Ogawa et al may be better 8 
suited for studies where accurate reproduction of a complex cellular niche is 9 
crucial, while our system is more optimized for mechanistic studies in biliary 10 
development and therapeutics. 11 
 12 
Limitations 13 
There are two main limitations to our platform. Our system relies on a 14 
complex extracellular matrix (Matrigel). The composition of Matrigel is not fully 15 
defined while variation in the growth factor and protein contents of each batch 16 
could affect the efficiency of the final stage of our protocol. Furthermore, the 17 
use of matrigel could render the translation of our platform to Good 18 
Manufacturing Practice (GMP) conditions challenging and prevent in vivo 19 
applications towards cell based therapy and regenerative medicine. Another 20 
important consideration is the maturity of the generated cells. CLC organoids 21 
express both early and mature biliary markers and maintain some fetal 22 
characteristics corresponding more accurately to a stage between fetal and 23 
fully mature bile ducts. Consequently, prior to modeling adult biliary disorders 24 
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CLCs should be tested for the presence of the relevant mature markers and 1 
functionality. 2 
 3 
Experimental Design 4 
Our method describes the generation of hPSC-derived CLC organoids over a 5 
period of 26 days. Biliary differentiation is achieved through 5 key stages of 6 
recapitulating bile duct development (Figure 1). Our protocol starts with the 7 
plating of hPSCs on day 0 (d0), while we refer to the first day of differentiation 8 
as day 1 (d1). The first stage (d1-3) results in the generation of definitive 9 
endoderm (DE) cells. These cells correspond to the common progenitor from 10 
which the liver, lung, pancreas, alimentary tract and thyroid arise. 11 
Subsequently, DE cells are differentiated into Foregut Progenitor (FP) cells 12 
(stage 2, d4-8), which correspond to precursors of the liver, pancreas, lung 13 
and thyroid lineages found in the anterior portion of the embryonic alimentary 14 
canal. In the third stage (d9-12) FP cells are differentiated to hepatoblasts 15 
(HBs), bipotent progenitors of hepatocytes and cholangiocytes, which can 16 
give rise to both. The fourth stage (d13-16) results in biliary commitment of 17 
HBs and the generation of cholangiocyte progenitors (CPs), which represent 18 
early cholangiocytes forming the ductal plate in vivo. In the final stage of our 19 
method (d17-26) CPs form functional CLC organoids in 3D culture conditions. 20 
 21 
Starting population considerations We have demonstrated that this 22 
protocol is reproducible with 4 different hPSC lines 7 and embryonic stem (ES) 23 
cells22 (Figure 2). Variability in differentiation capacity is a common issue with 24 
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hPSC lines, which may reflect on the efficiency and timing of our protocol. 1 
Therefore, some minor optimization steps may be required for each hPSC-line 2 
as described in the following sections. 3 
 4 
Preparation of hPSCs To achieve high differentiation efficiency the 5 
generation of a near homogeneous DE population is crucial. For that hPSCs 6 
have to exhibit optimal morphology and minimal background differentiation. 7 
They should first be allowed to grow to near confluence (70-80%), then they 8 
are broken into small clumps and plated at high density as described in the 9 
sections below (Figure 1b; Steps 1-9). Clump size and density plays a critical 10 
role in this step. Very small clumps or single cells are not viable after the first 11 
day of differentiation, while large clumps differentiate only partially, 12 
maintaining the expression of pluripotency markers at their center. Low 13 
densities prevent the cells from reaching near confluence by the end of the 14 
first stage. This can have a negative impact on paracrine signaling, cell 15 
migration and cell to cell contact, which are crucial factors for efficient 16 
formation of the foregut epithelium. A minimum of 24 hours is allowed for the 17 
hPSCs to adhere to the plate before starting differentiation; however this 18 
period can be extended to a maximum of 48 hours if the clump size is thought 19 
to be too small. 20 
 21 
Generation of Definitive Endoderm and Foregut Progenitors Definitive 22 
endoderm differentiation is characterized by morphological changes; 23 
epithelial-mesenchymal transition (EMT; Figure 1b); significant proliferation of 24 
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the cells and increased death of cells that fail to differentiate. By the end of 1 
day 3 the cells should be approaching confluence (Figure 1b) and express 2 
Sox17 and EOMES homogeneously (>90%, Figure 3-4). Cell proliferation 3 
continues during the FP stage and by the end of day 8 the cells should be 4 
forming a confluent epithelium with cells exhibiting a characteristic rhomboidal 5 
morphology (Figure 1b). The generation of a near homogeneous population of 6 
FP cells is crucial for the efficiency of later stages. Therefore, we recommend 7 
that differentiations are optimized to generate cell populations with >95% 8 
purity for endoderm and foregut markers (Figure 3-4), such as GATA4 and 9 
FOXA2. In particular, for resistant hPSC lines with significant contamination 10 
from partially differentiated cells, we recommend splitting the cells at the 11 
foregut stage (d6).  For lines with lower proliferation rates and good 12 
differentiation efficiency this step is optional. If the cells are split at this stage it 13 
is very important that they are dissociated to single cells and re-plated at a 14 
density allowing the formation of a fully confluent epithelium by d8. 15 
 16 
Generation of bipotent hepatoblasts Cell proliferation begins to reduce at 17 
this stage, although cells should continue to proliferate at a lower rate. We 18 
have noticed variability in proliferation rate between different hPSC lines. 19 
Differentiation of FP to HBs should result in a near homogeneous population 20 
(>95%) expressing hepatoblast markers (CK19, AFP) (Figure 3-4), which is 21 
important for the efficiency of subsequent steps. High cell density of FPs 22 
forming a monolayer of relatively small cells is crucial for the success of this 23 
stage. For resistant hPSC lines this stage could be prolonged by 24hrs to 24 
improve differentiation efficiency. However, significant prolongation of HB 25 
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differentiation carries the risk of committing a significant proportion of cells to 1 
the hepatic lineage which results in increased hepatoblast/ hepatocyte 2 
contamination in the next stage and reduced biliary lineage commitment.  3 
Generation of cholangiocyte progenitors Cell proliferation should increase 4 
compared to the previous stage and by the fourth day of cholangiocyte 5 
progenitors differentiation significant overgrowth should be seen (100% 6 
confluence and/or areas of cells forming multiple layers). Differentiation of 7 
HBs to CPs is heterogeneous, resulting in a mixed population of CPs (75%), 8 
HBs (15%) and cells at intermediate stages (Figure 4). Consequently, hepatic 9 
markers, such as AFP can still be detected, but early biliary markers such as 10 
CK19 and SOX9 should also be expressed almost homogeneously (Figure 2, 11 
3). Poor efficiency at this stage (<75% SOX9 positive cells) could result in 12 
incomplete maturation of CLC organoids in the next step. The quality and 13 
duration of the HB stage is critical to limit HB contamination and ensure biliary 14 
commitment.  15 
 Therefore, for resistant hPSC lines we recommend optimizing the duration 16 
and efficiency of HB differentiation as described in the previous section  17 
(Generation of bipotent hepatoblasts) and in the troubleshooting section 18 
(Table 1). 19 
Generation of CLC organoids For the final stage of our protocol CPs are 20 
dissociated into small clumps and transferred to 3D culture conditions. 21 
Density and clump size are the most critical factors for the success of this 22 
step. Very high densities do not allow adequate space for the cells to expand 23 
and re-organize into organoids with a central lumen. Instead, proliferating 24 
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clumps of cells merge together into large aggregates. Single cells or very 1 
small clumps may not be viable, while large clumps gradually migrate and 2 
attach to the bottom of the plate forming a monolayer. Consequently, the 3 
efficiency of this phase depends on careful manipulation of the quantity of 4 
cells, matrigel and media. Minor adjustments to density and clump size may 5 
be required for different hPSC lines (see troubleshooting and procedures 6 
sections, steps 17-26). For resistant lines such as H9, we recommend adding 7 
forskolin (optional step), which promotes intraluminal fluid secretion and 8 
facilitates the formation of organoids with a lumen. 9 
Of note this step starts with a heterogeneous population of cells including HBs 10 
and CPs and thus some hepatic contamination is expected. However, cells 11 
expressing hepatic markers, such as AFP fail to form organoids and usually 12 
gravitate to the bottom of the plate. On the contrary, by the end of this stage 13 
CLC organoids should express biliary (CK19, CK7, SOX9) (Figure 3-4) but not 14 
hepatic markers (AFP) and demonstrate functional properties characteristic of 15 
biliary epithelium, such as GGT and ALP activity (Figure 5). Importantly, we 16 
have noticed differences in differentiation efficiency with different batches of 17 
Matrigel. For resistant hPSC lines Matrigel should be screened for batches 18 
which support organoid formation and cholangiocyte functionality. 19 
 20 
Controls 21 
Intrahepatic cholangiocytes are not commercially available. Therefore, we 22 
recommend the use of fresh bile duct tissue obtained from liver donors, or 23 
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frozen isolated common bile duct cholangiocytes commercially available 1 
(Celprogen) as a positive control for the expression of biliary markers. 2 
 3 
MATERIALS 4 
 5 
REAGENTS 6 
CRITICAL All the reagents listed are reconstituted and stored as per the 7 
manufacturer’s instructions unless specifically stated 8 
hPSCs. All hPSC lines were derived by the Cambridge Biomedical Research 9 
Campus (BRC) hIPSC core facility (ethics reference no. 08/H0311/201 for 10 
Hertfordshire Regional Ethics Committee (REC) and 09/H0304/77 for National 11 
Research Ethics Service (NRES) Committee East of England, Cambridge 12 
East) CAUTION HPSC derivation should always occur in compliance with 13 
appropriate national laws and institutional regulations. Informed consent must 14 
be obtained from human subjects. CAUTION The cell lines used in your 15 
research should be regularly checked to ensure they are authentic and are 16 
not infected with mycoplasma. 17 
Gelatin (Sigma, cat. no. G1890) 18 
Water for embryo transfer (Sigma, cat. no. W1503) 19 
Advanced DMEM F12 (Life Technologies, cat. no. 12634028) 20 
Penicillin-streptomycin (Life Technologies, cat. no. 15140122) 21 
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L-Glutamine (Life Technologies, cat. no. 25030024) 1 
β-Mercaptoethanol (Sigma, cat. no. M6250) CAUTION β-Mercaptoethanol is 2 
toxic if ingested, inhaled, or following prolonged skin exposure. Wear 3 
protective clothing and use a fume hood. 4 
FBS (Life Technologies, cat. no. 10500064) CRITICAL Due to batch-to-batch 5 
variability in serum, serum batches should be screened for their capacity to 6 
maintain pluripotency for a minimum of 2 passages. Key features of 7 
pluripotent cell growth include characteristic colony morphology, differentiation 8 
potential to all 3 germ layers and expression of pluripotency markers such as 9 
NANOG, POU5F1 and SOX2. 10 
Ham's F-12 Nutrient Mix, GlutaMAX™ Supplement (Life Technologies, cat. 11 
no. 31765068) 12 
Iscove's Modified Dulbecco's Medium (IMDM) (Life Technologies, cat. no. 13 
21980065) 14 
Chemically defined lipid concentrate (Life Technologies, cat. no. 11905031) 15 
Monothioglycerol (Sigma, cat. no. M6145) 16 
Transferrin (30 mg/ml, Roche, cat. no. 652202) 17 
Insulin, 10 mg/ml (Roche, cat. no. 1376497) 18 
Poly(vinyl alcohol) (PVA) 87-90% hydrolyzed (Sigma, cat. no. P8136) 19 
KnockOut serum replacement (KOSR; Life Technologies, cat. no. 10828028) 20 
Collagenase IV (Life Technologies, cat. no. 17104019) 21 
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Dispase   (Invitrogen, cat. no. 17105041) 1 
DMEM F-12 (Life Technologies, cat. no. 11330032) 2 
RPMI 1640 + GlutaMAX (Gibco, cat. no. 61870) 3 
B-27 supplement containing insulin (Gibco, cat. no. 17504-044) CRITICAL 4 
Due to batch-to-batch variability in B27, B27 batches should be screened for 5 
their capacity to support HB and CP differentiation in a minimum of 2 different 6 
differentiation experiments. HB and CP differentiation should be assessed 7 
based on appropriate markers on flow cytometry analyses. These include 8 
>95% expression of CK19 and AFP for HBs and >75% expression of Sox9 9 
and CK19 for CPs (Figure 4). 10 
MEM non-essential amino acids (MEM-NEAA; Gibco, cat. no. 1140) 11 
Dulbecco’s PBS (DPBS; Life Technologies, cat. no. 14190)  12 
Cell Dissociation Buffer, enzyme-free, PBS (Gibco, cat. no. 13151014) 13 
William's E Medium, no phenol Red (Invitrogen, cat. no. A12176-01) 14 
Dexamethasone (R&D systems, cat. no. 1126/100) 15 
DMSO (Sigma, cat. no. D2650) 16 
ITS+ Universal Cell Culture Supplement Premix, 20 ml, 2 L equivalent 17 
(Corning, cat. no. 354352) 18 
Nicotinamide (Sigma, cat. no. N0636) 19 
D-Glucose (Invitrogen, cat. no. 15023021) 20 
Sodium bicarbonate powder (Sigma, cat. no. S5761) 21 
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2-Phospho-L-Ascorbic Acid Trisodium Salt (Sigma, cat. no. 49752) 1 
HEPES Solution (Sigma, cat. no. H0887-20ML) 2 
Sodium Pyruvate (Invitrogen, cat. no. 11360-070) 3 
Recombinant human Activin A (R&D Systems, cat. no. 338-AC) 4 
Recombinant human BMP4 (R&D Systems, cat. no. 314-BP) 5 
Recombinant human FGF basic, 146 aa (R&D Systems, cat. no. 233-FB) 6 
LY294002 (Promega, cat. no. V1201) 7 
CHIR99021 (Tocris, cat. no. 4423) 8 
SB431542 (Tocris bioscience, cat. no. 1614) 9 
Recombinant Human Keratinocyte Growth Factor-2 (FGF10) (Source 10 
Bioscience, cat. no. ABC144) 11 
Retinoic acid (Sigma, cat. no. R2625) 12 
Y27632 (ROCK Inhibitor) (Selleck, cat. no. S1049)  13 
Matrigel (BD Biosciences, cat. no. 356237) CRITICAL Due to batch-to-batch 14 
variability in matrigel, matrigel batches should be screened for their capacity 15 
to support organoid formation and maturation in a minimum of 2 different 16 
differentiation experiments. Organoids should be clearly identified following 5 17 
days of culture in matrigel, while small ring structures can be seen as early as 18 
48-72 hours. CLC maturation should be assessed based on appropriate 19 
marker expression on flow cytometry analyses and functional assays. These 20 
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include >75% expression of Sox9 and CK7, ALP and GGT activity (Figure 3-1 
5). 2 
Recombinant Human EGF Protein (R&D Systems, cat. no. 236-EG) 3 
Cell recovery solution (SLS, cat. no. 354253) 4 
Donkey serum (abd serotec, cat. no. c06sb) 5 
Triton-X100 solution (Sigma, cat. no. X100-500ML) 6 
Parafolmadehyde 16% w/v (PFA; Alfa Aesar, cat. no. 30525-89-4) 7 
GenElute™ Mammalian Total RNA Miniprep Kit (Sigma, cat. no. RTN-350) 8 
TrypLE™ Express Enzyme (1X), no phenol red (Gibco, cat. no. 12604021) 9 
Cytokeratin 7 antibody (RCK105) (Abcam, cat. no. ab9021; Table 2) 10 
Cytokeratin 7 antibody (Abcam, cat. no. ab68459; Table 2) 11 
Cytokeratin 19 antibody (Abcam, cat. no. ab7754; Table 2) 12 
SOX9 H-90 antibody (Santa Cruz, cat. no. sc-20095; Table 2) 13 
TBX3 (A-20) antibody (Santa Cruz, cat. no. sc-17871; Table 2) 14 
HNF4 (H-171) antibody (Santa Cruz, cat. no. sc-8987; Table 2) 15 
Alpha fetoprotein (AFP) antibody (DAKO, cat. no. A0008; Table 2) 16 
Sox17 antibody (R&D, cat. no. AF1924; Table 2) 17 
TBR2 / Eomes antibody - (Abcam, cat. no. ab23345; Table 2) 18 
GATA4 (G-4) antibody (Santa Cruz, cat. no. sc-25310; Table 2) 19 
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HNF3b/FoxA2 antibody (R&D, cat. no. AF2400; Table 2) 1 
Oct-3/4 (H-134) antibody (Santa Cruz, cat. no. sc-9081; Table 2) 2 
Anti-human NANOG antibody (R&D, cat. no. AF1997; Table 2) 3 
MaxDiscovery™ gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit 4 
(Bioo Scientific, 5601-01) 5 
BCIP/NBT Color Development Substrate (Promega, S3771) 6 
 7 
EQUIPMENT 8 
CO2 incubator (Sanyo, cat. no. MCO-18AC) 9 
Centrifuge (Eppendorf, cat. no. 5804) 10 
Counting chamber (Superior Marienfeld, cat. no. 0640410) 11 
Disposable serological pipettes, 5 10 and 25 ml (Corning, cat. nos. 4487, 12 
4488 and 4489) 13 
Graduated filter tips, 1,000 μl, 200 μl, 20 μl, 10 μl (Starlab, cat. nos. S1122-14 
1830, S1120-8810, S1120-1810, S1120-3810) 15 
Centrifuge tubes, 15 ml and 50 ml (Corning, cat. no. 430791 and 430291) 16 
500mL Vacuum Filter/Storage Bottle System, 0.22µm Pore (Corning, cat. no. 17 
431097) 18 
100mm TC-Treated Culture Dish (Corning, cat. no. 430167) 19 
19 
 
Costar® 12 Well Clear TC-Treated Multiple Well Plates (Corning, cat. no. 1 
3513) 2 
Costar® 24 Well Clear TC-Treated Multiple Well Plates (Corning, cat. no. 3 
3526) 4 
Plate heater (TAP Biosystem, cat. no. 016-0R10) 5 
Inverted microscope (Olympus, cat. no. CKX41) 6 
 7 
REAGENT SETUP 8 
Gelatin for coating tissue culture plates (500 ml)  9 
Dissolve 0.5g of gelatin into 500mls of water for embryo transfer. Heat at 56oC 10 
until the gelatin has fully dissolved (approximately 30 minutes). CRITICAL 11 
Sterilize gelatin solution using a vacuum filter/storage bottle system. Store at 12 
room temperature (18–25 °C) for up to 1 month 13 
Serum-containing medium for coating tissue culture plates (500 ml) 14 
Add 50 ml of FBS, 5 ml of glutamine, 5 ml of penicillin-streptomycin 15 
(pen/strep) and 3.5 μl of β-mercaptoethanol in 450 ml of Advanced 16 
DMEM/F12. CRITICAL Sterilize serum-containing medium using a vacuum 17 
filter/storage bottle system. Mix well before filtration. Store at 4 °C for up to 1 18 
month. 19 
Chemically Defined Medium – PVA (CDM-PVA) medium for maintenance 20 
of hPSCs 21 
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Combine 0.5 g of PVA, 250 ml of F12 + GlutaMAX, 250 ml of IMDM, 5 ml of 1 
concentrated lipids, 20 μl of thioglycerol, 350 μl of insulin, 250 μl of transferrin 2 
and 5 ml of pen/strep. Store at 4 °C for up to 1 month. Dissolve PVA in IMDM 3 
by adding 0.5 g of PVA to 50 ml of IMDM and mixing overnight at 4 °C (e.g. 4 
using a 50 ml falcon on a roller). CRITICAL Sterilize CDM-PVA medium using 5 
a vacuum filter/storage bottle system. Mix well before filtration. Warm to 37 °C 6 
before use. 7 
Collagenase, 500 ml 8 
Dissolve 500 mg of Collagenase IV into 400 ml of Advanced DMEM/F12 9 
combined with 100 ml of Knockout Serum Replacer, 5 ml of L-Glutamine, 3.5 10 
μl of β-Mercaptoethanol. CRITICAL Sterilize collagenase using a vacuum 11 
filter/storage bottle system. Mix well before filtration. Store at 4 °C for up to 1 12 
month. Warm to 37 °C before use. 13 
Dispase, 500 ml 14 
Dissolve 500 mg of Dispase into 500 ml of DMEM F-12. CRITICAL Sterilize 15 
dispase using a vacuum filter/storage bottle system. Mix well before filtration. 16 
Store at 4 °C for up to 1 month. Warm to 37 °C before use. 17 
1:1 Collagenase/Dispase solution for dissociation of hPSCs 18 
Warm collagenase and dispase to 37 °C. Mix 1 volume of collagenase with 1 19 
volume of dispase immediately before use. The volumes used are dependent 20 
on the number and type of plates used. For each 10 cm plate mix 3 ml of 21 
collagenase with 3 ml of dispase. 22 
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RPMI/B-27 differentiation medium for the differentiation of FP, HBs and 1 
CPs (500 ml)  2 
Add 10 ml of B-27, 5 ml of NEAA and 5 ml of pen/strep into 500 ml of RPMI-3 
1640. CRITICAL We have noticed variation between different batches of B-4 
27. B-27 batches should be screened for the capacity to support FP, HB and 5 
CP differentiation. Appropriate markers for the efficiency of each stage are 6 
provided in the experimental design section. Store at 4 °C for a maximum of 3 7 
weeks. Warm to 37 °C before use. 8 
Nicotinamide 0.4M stock solution  9 
Dissolve 24.4 g of nicotinamide powder in 500 ml of embryo transfer water. 10 
CRITICAL Sterilize nicotinamide stock solution using a vacuum filter/storage 11 
bottle system. Mix well before filtration. Store at 4 °C for up to 3 months. 12 
Sodium Bicarbonate 1M stock solution preparation 13 
Dissolve 42 g of sodium bicarbonate powder in 500 ml of embryo transfer 14 
water. CRITICAL Sterilize sodium bicarbonate stock solution using a vacuum 15 
filter/storage bottle system. Mix well before filtration. Store at 4°C for up to 3 16 
months. 17 
Ascorbic acid trisodium salt 100mM stock solution preparation 18 
Dissolve 16.1 g of Ascorbic acid trisodium salt powder in 500 ml of embryo 19 
transfer water. CRITICAL Sterilize ascorbic acid trisodium salt stock solution 20 
using a vacuum filter/storage bottle system. Mix well before filtration. Store at 21 
4 °C for up to 3 months. Protect from light. 22 
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D-Glucose 1M stock solution preparation  1 
Dissolve 90.1 g of D-glucose powder in 500 ml of embryo transfer water. 2 
Warm to 50°C to facilitate dissolution CRITICAL Sterilize D-glucose stock 3 
solution using a vacuum filter/storage bottle system. Mix well before filtration. 4 
Store at 4 °C for up to 3 months. 5 
Dexamethasone 10 mM stock solution 6 
Dissolve 100 mg of Dexamethasone in 25.4797 ml of DMSO. Aliquot in 50-7 
100 μl aliquots. Store in -80oC for up to 12 months. 8 
Supplemented William’s E medium for the maturation of CPs to CLCs in 9 
3D culture 10 
Combine 443 ml of William’s E (WE) medium with 12.5 ml nicotinamide stock 11 
solution, 8.5 ml sodium bicarbonate stock solution, 1 ml ascorbic acid 12 
trisodium salt stock solution, 7 ml glucose stock solution, 3.15 ml sodium 13 
pyruvate, 10 ml HEPES solution, 5 ml ITS+ premix, 5 μl dexamethasone 14 
(R&D Systems), 5.3 ml Glutamine and 5 ml pen/strep. CRITICAL Sterilize 15 
supplemented WE medium using a vacuum filter/storage bottle system. Mix 16 
well before filtration. Store at 4°C for up to 1 month. Warm to 37 °C before 17 
use. 18 
Matrigel preparation 19 
10 ml matrigel vials should be thawed slowly in an icebox placed at 4oC 20 
overnight. Thawed matrigel should be mixed well and then aliquoted in 1 ml 21 
aliquots. Aliquoting of matrigel should always happen in a tissue culture hood 22 
to avoid bacterial contamination. Matrigel should be kept constantly on ice to 23 
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avoid solidification. All equipment coming in contact with matrigel should be 1 
pre-cooled to 4oC. This includes pipette tips and media for diluting matrigel. 2 
Tubes for aliquoting should be kept on ice. Store matrigel aliquots at -20°C or 3 
-80°C for up to 3 months. CRITICAL Each aliquot should undergo a maximum 4 
of 2 freeze thaw cycles. This can be achieved by adjusting aliquot volumes 5 
accordingly. 6 
50%(vol/vol) matrigel solution preparation 7 
Add 1 volume of supplemented WE medium to 1 volume of matrigel and mix 8 
thoroughly. CRITICAL The supplemented WE medium should be pre-cooled 9 
to 4oC. CRITICAL Both matrigel and the supplemented WE medium should 10 
be kept on ice during and after the preparation of the 50% (vol/vol) solution to 11 
avoid solidification. 12 
To calculate the volume of supplemented WE medium and matrigel that need 13 
to be mixed please use the following formula:  14 
Volume of supplemented WE = [(number of 24-plate wells) x 50 μl] / 2 15 
The number of wells is multiplied by 50 μl which corresponds to the volume of 16 
each dome and divided by 2 to reflect the matrigel-media ratio (50% or 1:1)  17 
 18 
EQUIPMENT SETUP 19 
Gelatin/serum-coated tissue culture plates 20 
Add enough gelatin solution to fully cover the surface of the plate. Indicative 21 
volumes are 6 ml for a 10 cm plate and 1 ml for each well of a 12-well plate. 22 
24 
 
Coat for a minimum of 30 min at room temperature, then aspirate the gelatin 1 
and replace with enough volume of serum-containing medium to fully cover 2 
the surface of the plate. Indicative volumes are 6 ml for a 10 cm plate and 1 3 
ml for each well of a 12-well plate. Store in an incubator at 37 °C for up to 1 4 
week. CRITICAL Allow a minimum of 24 hours at 37 °C before using the 5 
plate. 6 
Plate heater setup 7 
Clean the plate heater with trigene and 70%(vol/vol) ethanol and place in a 8 
tissue culture hood. Set the temperature to 37 °C and place a 24 well plate on 9 
the heating surface CRITICAL Allow a minimum of 30 minutes for the plate to 10 
warm up, prior to plating matrigel with cells. If you are using multiple plates 11 
these can be pre-warmed in an incubator for a minimum of 30 minutes with 12 
each plate placed on the plate heater immediately before plating.  13 
 14 
PROCEDURE  15 
Passaging of hPSCs TIMING 1 d 16 
1 Ensure that hPSC colonies are growing and maintaining their characteristic 17 
morphology23. We recommend using lines which have been stable in culture 18 
for at least 10 passages. Change the medium daily using CDM-PVA 19 
supplemented with Activin (10 ng/ml) and bFGF (12 ng/ml). Proceed to the 20 
next step when the cells are 70-80% confluent.  21 
2 Aspirate the medium and wash the plate with Ca2 + /Mg2 + -free PBS. The 22 
volume of PBS depends on the type of plate used. Indicative minimum 23 
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volumes are 6 ml for a 10 cm plate, 1-2 ml for a well of a 6-well plate and 0.5 1 
ml for a well of a 12-well plate. 2 
3 Aspirate the PBS and add the appropriate volume of 1:1 3 
collagenase/dispase solution. Refer to step 2 for indicative volumes. Incubate 4 
at 37 °C for 30-60 min until the majority of the colonies (>90%) have 5 
detached. 6 
4 Tilt the plate and wait for the colonies to gravitate to its lowest part forming a 7 
loose pellet. Using a 1000 μl pipette harvest the cells and transfer to a 15 ml 8 
tube containing 6 ml of CDM-PVA.  9 
5 Allow 1-2 minutes for the colonies to settle to a loose pellet. Aspirate the 10 
supernatant and add 6 ml of CDM-PVA. Repeat this step twice for a total of 2 11 
washes with CDM-PVA. 12 
6 Aspirate the supernatant and re-suspend the pellet in 1 ml of CDM-PVA 13 
supplemented with Activin (10 ng/ml) and bFGF (12 ng/ml). CRITICAL STEP 14 
Using a 1000 μl pipette gently break the colonies into small clumps. Clump 15 
size can effect differentiation efficiency. Aim for clumps of 50–100 cells 16 
(Figure 1b). 17 
7 Prepare new plates by washing gelatin coated plate with PBS as described 18 
in step 2. Aspirate the PBS and add the appropriate volume of CDM-PVA 19 
supplemented with Activin (10 ng/ml) and bFGF (12 ng/ml) as described in 20 
step 2 21 
8 Add 100 μl of the cell suspension (step 6) to each 10 cm dish. CRITICAL 22 
STEP hPSCs should be plated in a density that will allow them to reach 80% 23 
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confluence in 6 – 8 days for maintenance plates and 3-6 days for 1 
differentiation (Figure 1b). This is usually achieved by using a 1:6 – 1:10 split 2 
ratio. Adjust the volume of cell suspension added to each plate based on your 3 
split ratio. Optimal split ratios vary and need to be adjusted for each individual 4 
hPSC-line depending on its growth parameters. A typical plating density for 5 
our lines is 200,000 cells per 10 cm plate for maintenance and 500,000 – 6 
1,000,000 cells for differentiation 7 
9 Incubate the cells at 37 °C overnight 8 
Differentiation of hPSCs into definitive endoderm TIMING 3 d 9 
10 Day 1 Ensure hPSCs have fully attached after plating. Aspirate the 10 
medium and add freshly prepared CDM-PVA supplemented with Activin A 11 
(100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10 μM) and 12 
CHIR99021 (3 μM). Incubate the cells at 37 °C overnight 13 
? TROUBLESHOOTING 14 
11 Day 2 Replace the medium with freshly prepared CDM-PVA supplemented 15 
with Activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10 16 
μM). Incubate the cells at 37 °C overnight 17 
12 Day 3 Replace the medium with freshly prepared RPMI/B27 medium 18 
supplemented with Activin A (100 ng/ml) and bFGF (80 ng/ml). Incubate the 19 
cells at 37 °C overnight. The typical morphology of the cells at the end of this 20 
stage is demonstrated in figure 1b. A proportion of the cells can be further 21 
characterized with flow cytometry and IF for the expression of endoderm 22 
markers such as Sox17, anticipating >90% positive cells (Figure 3-4). 23 
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? TROUBLESHOOTING 1 
Differentiation of definitive endoderm into foregut progenitor cells 2 
TIMING 5 d 3 
13 Day 4-6 Replace the medium daily with freshly prepared RPMI/B27 4 
medium supplemented with Activin A (50 ng/ml).  5 
14 Day 7 Assess the homogeneity and morphology of the cells. The typical 6 
morphology of the cells on d7 is demonstrated in figure 1b. If cells exhibit 7 
optimal morphology with minimal contamination from undifferentiated or 8 
partially differentiated cells, then complete FP differentiation without splitting 9 
the cells (option A). For populations with sub-optimal morphological 10 
characteristics and significant contamination with poorly differentiated cells or 11 
if the cells are overgrown proceed to split the cells (option B). 12 
(A) Completion of FP differentiation without splitting TIMING 2d 13 
(i) Day 7-8 Replace the medium daily with freshly prepared RPMI/B27 14 
medium supplemented with Activin A (50 ng/ml) 15 
? TROUBLESHOOTING 16 
(B) Splitting cells and completion of FP differentiation TIMING 2d 17 
(i) Day 7 Prepare new plates as described in step 7 18 
(ii) Wash the cells once with PBS as described in step 2. Add the appropriate 19 
volume of cell dissociation buffer as described in step 2 and incubate at 37 °C 20 
for 20 min until the cells have detached. Tap the plate to facilitate detachment.  21 
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(iii) Transfer the cells in a 15 ml tube. Gently aspirate and re-suspend the cell 1 
solution using a 5 ml serological pipette, to facilitate dissociation to single 2 
cells.  3 
(iv) Wash the plate that contained the cells with 1 volume of RPMI/B27 4 
medium and transfer the wash to the 15 ml tube 5 
(v) Centrifuge at 444 g for 3 minutes. Aspirate the supernatant and resuspend 6 
the cells in 6 ml of RPMI/B27 medium. 7 
(vi) Use a counting chamber to count the number of cells in the suspension 8 
(vii) Centrifuge at 444 g for 3 minutes. Aspirate the supernatant and re-9 
suspend the cells the appropriate volume of freshly prepared RPMI/B27 10 
medium supplemented with Activin A (50 ng/ml) and Rho kinase inhibitor Y-11 
27632 (10 μm) for a final concentration of 1x106 cells/ml. 12 
CRITICAL STEP Y-27632 should always be freshly added and kept in the 13 
culture for a minimum of 24 hours to improve cell survival. 14 
(viii) Add the appropriate volume of cell suspension to the new plates to 15 
provide coverage of 150,000 cells / cm2. Ensure this is more than the 16 
minimum volume indicated in step 2 and supplement with freshly prepared 17 
RPMI/B27 medium supplemented with Activin A (50 ng/ml) if required. 18 
(ix) Incubate at 37 °C overnight 19 
CRITICAL STEP The density of the cells following the split may affect the 20 
efficiency of the later steps of differentiation. It is crucial to plate the cells at an 21 
appropriately high density so that the cells are almost confluent (90%) 22 
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following the split. In some cases not all the cells attach therefore it is crucial 1 
to look at the plates and if necessary, increase the cell number plated to 2 
achieve the right confluence Very high densities promoting growth of cells in 3 
overlapping layers also have a negative impact on differentiation efficiency 4 
and should be avoided. 5 
(x) Day 8 Replace the medium with freshly prepared RPMI/B27 medium 6 
supplemented with Activin A (50 ng/ml). Incubate at 37 °C overnight. Further 7 
characterize a proportion of the cells with IF and flow cytometry analyses for 8 
the expression of foregut markers such as GATA4 (Figure 3-4), anticipating 9 
>90% positive cells. 10 
CRITICAL STEP The typical morphology of the cells at the end of this stage 11 
can be seen in figure 1b.  12 
? TROUBLESHOOTING 13 
Differentiation of foregut progenitor cells into hepatoblasts TIMING 4 d 14 
15 Day 9-12 Replace the medium daily with freshly prepared RPMI/B27 15 
medium supplemented with SB-431542 (10 μM) and BMP-4 (50 ng/ml). 16 
Monitor hepatoblast differentiation through the expression of HNF4A, AFP 17 
and TBX3 by IF and flow cytometry analyses. 18 
CRITICAL STEP The typical morphology of the cells is demonstrated in figure 19 
1b. Optimal hepatoblast differentiation is necessary for efficient differentiation 20 
of later stages. AFP expression should be observed in >95% of the cells by 21 
day 12 (Figure 3-4) 22 
? TROUBLESHOOTING 23 
30 
 
Differentiation of hepatoblasts into cholangiocyte progenitors TIMING 1 
4d 2 
16 Day 13-16 Replace the medium daily with freshly prepared RPMI/B27 3 
medium supplemented with FGF10 (50 ng/ml), Activin-A (50 ng/ml) and 4 
Retinoic acid (3μM). Monitor CP differentiation through the expression of Sox9 5 
which should be observed in >75% of the cells by day 16 (Figure 4). 6 
CRITICAL STEP The typical morphology of the cells is demonstrated in figure 7 
1b. Optimal CP differentiation is necessary for efficient differentiation of later 8 
stages. ? TROUBLESHOOTING 9 
Passaging of cholangiocyte progenitors and transfer to 3D culture 10 
conditions TIMING 1-2h 11 
CRITICAL Prior to starting this step ensure that the matrigel and related 12 
equipment is prepared as described in the reagent setup section and the plate 13 
heater and the required number of plates are prepared as described in the 14 
equipment setup section.  15 
17 Day 17 Wash the cells once with PBS and add the appropriate volume of 16 
cell dissociation buffer as described in step 2. Incubate at 37 °C for 20 min.  17 
18 Tap the plate to facilitate detachment. The cells should detach as a 18 
monolayer or large clumps. If no detachment can be identified after 20 min 19 
proceed to mechanical dissociation with a pipette using a combination of 20 
horizontal, perpendicular and circular movements. We used a 1000 μl pipette 21 
for harvesting cells from 1 well of a 12-well plate. 22 
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19 Transfer the cells in a 15 ml tube. Gently aspirate and re-suspend the cell 1 
solution 2-3 times, using a 1000 μl pipette, to facilitate dissociation to small 2 
clumps.  3 
CRITICAL STEP Clump size is crucial for the efficiency of the following 4 
differentiation step and the formation of organoids. Aim for clumps of 10-50 5 
cells. Very small clumps and single cells exhibit poor survival, while large 6 
clumps gravitate to the bottom of the plate and fail to form organoids. 7 
Optimization of clump size may be required between different lines 8 
? TROUBLESHOOTING 9 
20 Wash the plate that contained the cells with 1 volume of RPMI/B27 10 
medium and transfer the wash to the 15 ml tube Centrifuge at 444 g for 3 11 
minutes. Aspirate the supernatant and resuspend the cells in 6 mls of 12 
RPMI/B27 medium. 13 
21 Centrifuge at 444 g for 3 minutes. Aspirate the supernatant.  14 
22 Re-suspend the cells in the appropriate volume of freshly prepared 50% 15 
(vol/vol) matrigel supplemented with EGF (20 ng/ml) and Rho kinase inhibitor 16 
Y-27632 (10 μm). Mix thoroughly. CRITICAL STEP Cholangiocyte progenitors 17 
should be plated in a density that will allow the emerging CLC organoids to 18 
reach 80% confluence in 10 days. This is usually achieved by using a 1:6 – 19 
1:10 split ratio (1 well of a 12-well plate split to 10 wells of a 24-well plate). 20 
Optimal split ratios vary and need to be adjusted for each individual hPSC-line 21 
depending on its growth parameters and differentiation efficiency. A typical 22 
plating density for our lines is 1 – 2 x105 cells 23 
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CRITICAL STEP The 50% (vol/vol) matrigel cell suspension should be kept 1 
on ice at all times to avoid solidification 2 
23 Mix the 50% (vol/vol) matrigel cell suspension thoroughly while keeping on 3 
ice. CRITICAL STEP Ensure 24 well plates have been placed on a plate 4 
heater or an incubator at least 30 min prior to plating, as described in the 5 
equipment setup section. Plating of the 50% (vol/vol) matrigel cell suspension 6 
should happen with the plate on the plate heater. 7 
24 To form a matrigel dome in one well of a 24 well plate hold the tip of the 8 
1000 μl pipette close to the surface of a well and start pipetting 50 μl of the 9 
50% (vol/vol) matrigel cell suspension until a small droplet forms. Lower the 10 
pipette tip so that the droplet touches the warm plate surface and gently 11 
pipette the remainder of 50 μl. CRITICAL STEP Ensure that the droplet does 12 
not touch the walls of the well, which could lead to collapse of the matrigel 13 
dome. 14 
25 Allow 1-2 minutes for the 50% (vol/vol) matrigel cell suspension to solidify. 15 
This can be assessed by gently tilting the plate. Turn the plate upside down 16 
and incubate at 37 °C for 30 min. 17 
26 Add enough supplemented WE with EGF (20 ng/ml) and Rho kinase 18 
inhibitor Y-27632 (10 μm) to cover the matrigel domes. For 1 well of a 24 well 19 
plate we use 1ml of media. 20 
CRITICAL STEP Y-27632 should always be freshly added and kept in the 21 
culture for a minimum of 24 hours to improve cell survival.  22 
? TROUBLESHOOTING 23 
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Differentiation of cholangiocyte progenitors into Cholangiocyte-like Cell 1 
(CLC) organoids TIMING 10d 2 
27 Day 17-26 Replace the medium  every 2 days daily with freshly prepared 3 
supplemented WE medium with EGF (20 ng/ml). Organoids should start 4 
forming following 2-4 days of culture. Monitor CLC differentiation can be 5 
through the expression of CK7 which should be observed in >75% of the cells 6 
by day 26 (Figure 4), positive ALP staining (Figure 5a) and GGT activity 7 
(Figure 5b) of CLC organoids. 8 
CRITICAL STEP The typical morphology of the cells is demonstrated in figure 9 
1b and Supplementary Fig. 1.  10 
? TROUBLESHOOTING 11 
Characterization of CLC organoids 12 
Immunofluorescence TIMING 2d 13 
CRITICAL A matrigel dilution of 50% (vol/vol) or less should be used for the 14 
generation of CLC organoids for staining to allow adequate antibody 15 
penetration 16 
28 Day 1 Aspirate the culture medium 17 
29 Add 1ml of 4% (wt/vol) PFA per well of a 24-well plate, for 20 minutes at 18 
room temperature to fix CLC organoids in matrigel  19 
30 Aspirate the PFA  20 
31 Wash twice with PBS (10 minutes/wash) 21 
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32 Permeabilize and block for 1 hour with a 10% (vol/vol) donkey serum and 1 
0.1% (vol/vol) Triton-X100 solution in PBS at room temperature 2 
33 Stain overnight at 4oC with primary antibody diluted in a solution of 1% 3 
(vol/vol) donkey serum and 0.1% TritonX-100 in PBS.  4 
34 Day 2 Wash 3 times with PBS (45 mins/wash)  5 
35 Stain the CLC organoids for 1 hour at room temperature with secondary 6 
antibody raised in donkey and diluted 1:1000 (vol/vol) in a solution of 1% 7 
(vol/vol) donkey serum and 0.1% TritonX-100 in PBS.  8 
36 Aspirate the secondary antibody 9 
37 Add a solution of Hoechst 33258 1:10000 (vol/vol) in PBS for 10 minutes at 10 
room temperature 11 
38 Wash 3 times with PBS (45 mins/wash).  12 
39 Image using a confocal microscope. All IF images (Figure 2-3) were 13 
acquired using a Zeiss LSM 700 confocal microscope. Imagej 1.48k software 14 
(Wayne Rasband, NIHR, USA, http://imagej.nih.gov/ij) was used for image 15 
processing such as merging of different channels.   16 
? TROUBLESHOOTING 17 
Extraction of CLCs from matrigel for further analyses  TIMING 40min. 18 
40 Aspirate the medium 19 
41 Add 500μl/well of a 24-well plate cell recovery solution 20 
35 
 
42 Mechanically dissociate the matrigel and CLC organoids by scrapping with 1 
the tip of a P1000 pipette and transfer to a 15 ml falcon tube.  2 
43 Incubate the resulting suspension of fragments of matrigel/CLC organoids 3 
in cell recovery solution for 30 minutes at 4oC 4 
44 Centrifuge at 444 g, for 4 minutes 5 
45 Aspirate the supernatant 6 
46 Wash twice with supplemented WE medium.  7 
47 Harvest and lyse CLC organoids for RNA extraction using any 8 
commercially available kit (we used the GenElute™ Mammalian Total RNA 9 
Miniprep Kit) or dissociate into single cells for flow cytometry following 10 
incubation with TrypLE for 5 minutes at 37oC.  11 
 12 
TIMING 13 
  14 
Steps Description Timing 
1-9 Passaging of hPSCs 1 day 
10-12 Differentiation of hPSCs into definitive endoderm 3 days 
13-14 Differentiation of definitive endoderm into foregut 
progenitor cells 
5 days 
15 Differentiation of foregut progenitor cells into hepatoblasts 4 days 
16 Differentiation of hepatoblasts into cholangiocyte 
progenitors 
4 days 
17-26 Passaging of cholangiocyte progenitors and transfer to 
3D culture conditions 
1-2 hrs 
27 Differentiation of cholangiocyte progenitors into CLC 
organoids 
10 days 
28-39 IF staining of CLC organoids 2 days 
40-47 Extraction of cells from matrigel for further analyses 40mins 
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See Table 1 for Troubleshoot guidance 1 
 2 
ANTICIPATED RESULTS 3 
We describe a methodology for the differentiation of hPSCs into functional 4 
CLC organoids in 26 days . The early stages of our protocol (DE, FP, HB) 5 
result in > 90% cells expressing endoderm and then FP markers (Figure 4). 6 
However, biliary specification of hepatoblasts results in 75% CK19+/SOX9+ 7 
CPs, which mature to a population of 75% CK7+ CLCs during the final step of 8 
our differentiation (Figure 4). The resulting CLC organoids should express 9 
biliary markers such as CK19 and CK7 in immunofluorescence (IF) analyses 10 
(Figure 2-3). Hepatic markers (AFP, Albumin) can still be detected in these 11 
stages due to the presence of a contaminating population of hepatic lineage 12 
cells, but these should be identified only in clumps of cells without a lumen or 13 
attached to the bottom of the plate. Furthermore CLC organoids could be 14 
validated further for additional cholangiocyte markers such as CFTR, AE2, 15 
Secretin receptor7,24 and should demonstrate functional properties such as 16 
luminal accumulation of Rhodamine-123, GGT and ALP activity (Figure 5). 17 
The methods used to characterize CLC organoids (flow cytometry, 18 
immunofluorescence, Rhodamine-123 accumulation, GGT activity and ALP 19 
staining) have been described elsewhere 7.  20 
Our platform promotes significant cell expansion. Using 3 different hPSC 21 
lines, we observed an average yield of >50x106 CLCs per 1x106 hPSCs. 22 
Proliferation should be particularly evident during the generation of CLC 23 
organoids. 1x105 CPs should give rise to 50-100 CLC organoids with 24 
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diameters ranging between 100-1000μm. However, variations in terms of the 1 
expansion potential and the differentiation efficiency of our protocol can occur. 2 
This can be attributed to inherent differences between hPSC lines and batch-3 
to-batch variability for some of the reagents including matrigel. For 4 
reproducible results the use of fresh medium and well-preserved small-5 
molecule, recombinant protein and matrigel stocks is essential. 6 
 7 
Table 1 TROUBLESHOOTING 8 
Step Problem Possible reason Solution 
10 Poor attachment 
of hPSCs  
Longer attachment 
time required 
Repeat step 9 incubating 
the cells for 1 more day 
before proceeding to step 
10 
Colony size too small Break colonies into slightly 
bigger clumps which 
gravitate to the bottom of 
the plate more easily, 
facilitating attachment 
Variability between 
hPSC lines 
Add Rho kinase inhibitor Y-
27632 in the medium 
during passaging  
Poor FBS batch If this problem occurs with 
more than one line change 
FBS batch. Screening FBS 
batches may be required 
as outlined in the Reagents 
section 
12 Poor endoderm 
differentiation 
efficiency 
Suboptimal plating of 
hPSCs for 
differentiation 
Decrease clump size and 
increase plating density 
Variability between 
lines with different 
sensitivity to activin 
or Wnt signaling 
For particularly resistant 
lines optimize the dose of 
activin A in steps 10-12 and 
CHIR in step 10, by 
monitoring the impact of 
increased doses  in  the 
efficiency of endoderm 
differentiation 
14A, 
14B 
Poor FP 
differentiation 
Variability between 
lines  
For persistent 
contamination with poorly 
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efficiency differentiated cells split the 
cells using step 14B 
Suboptimal plating of 
cells following split in 
step 14B 
For poor differentiation 
efficiency following a split 
optimize cell density 
ensuring the cells are 
confluent by the following 
day 
Reduced activity of 
growth factors 
Check Activin-A activity 
Use growth factors that are 
within 5 freeze-thaw cycles 
Poor B27 batch For particularly resistant 
lines change B27 batch. 
Screening B27 batches 
may be required as 
outlined in the Reagents 
section 
14B Poor attachment 
following split 
Suboptimal plating of 
cells following split in 
step 14B 
Increase cell density 
Use a viability dye such as 
trypan blue when counting 
the cells to ensure the 
appropriate number of live 
cells are plated.  
Poor FBS batch If this problem occurs with 
more than one lines 
change FBS batch. 
Screening FBS batches 
may be required as 
outlined in the Reagents 
section 
15 Poor hepatoblast 
differentiation 
Suboptimal previous 
steps 
Check and optimize the 
differentiation efficiency to 
Foregut Progenitors 
Increase plating density in 
step 14B to ensure the 
cells are confluent by step 
15 
Reduced activity of 
growth factors 
Check SB431542 activity 
Use growth factors that are 
within 5 freeze-thaw cycles 
Variability between 
lines with different 
sensitivity to activin 
signaling 
For particularly resistant 
lines the dose of SB431542 
can be increased 
Poor B27 batch For particularly resistant 
lines change B27 batch. 
Screening B27 batches 
may be required as 
outlined in the Reagents 
section 
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16 Poor 
cholangiocyte 
progenitor 
differentiation 
Variability between 
lines with increased 
sensitivity to the 
previous 
differentiation stage 
resulting in hepatic 
commitment of the 
generated 
hepatoblasts 
Minimize hepatoblast 
contamination by 
optimizing the duration of 
the previous stage to avoid 
hepatic commitment of the 
cells. Aim for the minimum 
duration that allows 
upregulation of hepatoblast 
markers 
Reduced activity of 
growth factors 
Check activin-A and 
retinoic acid activity 
Increase the dose of 
Activin-A 
Use growth factors that are 
within 5 freeze-thaw cycles 
Variability between 
lines 
The differentiation 
efficiency of hPSC-derived 
hepatoblasts into 
cholangiocyte progenitors 
is dependent on the culture 
media. Optimization may 
be required for particularly 
resistant lines. Advanced 
DMEM/F12 can replace 
RPMI/B27 for selected 
lines. 
Poor B27 batch For particularly resistant 
lines change B27 batch. 
Screening B27 batches 
may be required as 
outlined in the Reagents 
section 
19 Clump size too 
small/ single cells 
following 
incubation with 
cell dissociation 
buffer 
Variability between 
lines 
Reduce the cell 
dissociation buffer 
incubation time 
For sensitive lines omit 
step 18 (incubation with cell 
dissociation buffer) and 
proceed to mechanical 
dissociation only in step 19 
If even mechanical 
dissociation alone results in 
single cells/ small clumps 
check cell density and plate 
the cells at higher density 
in step 14B 
26 Poor cell survival 
following transfer 
to 3D culture 
Variability between 
lines 
Optimize clump size. More 
sensitive lines may require 
larger clump sizes 
Optimize plating density. 
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Low plating densities are 
associated with poor 
survival 
Reduced activity of 
reagents 
Check Y-27632 activity and 
ensure it is freshly 
prepared 
Increased cell death 
secondary to 
vigorous mechanical 
dissociation 
Avoid vigorous mechanical 
dissociation of the cells 
during passaging 
27 Poor organoid 
formation and/ or 
poor CLC 
differentiation 
and/ or poor CLC 
function 
Suboptimal previous 
steps 
Check the differentiation 
efficiency of cholangiocyte 
progenitors 
Variability between 
lines 
Optimize clump size and 
plating density.. Aim for 
smaller clumps and lower 
density if there is significant 
attachment of cells to the 
bottom of the plate  
For resistant lines consider 
adding forskolin to the 
culture medium 
Poor matrigel batch For particularly resistant 
lines change matrigel 
batch. Screening matrigel 
batches may be required 
as outlined in the Reagents 
section 
39 Unsuccessful 
staining 
Poor antibody 
penetration 
Decrease the matrigel 
dilution to 40% 
Place the plate on a lab 
rocker during the staining 
and washing steps 
Difficulties acquiring 
optimal images in 3D 
while CLC organoids 
are embedded in 
matrigel 
Grow CLC organoids on 
chamber slides and use 
alternative staining method; 
remove chambers and 
snap freeze or repeat steps 
27-37 and use a cover slip 
to flatten organoids 
Inadequate 
optimization for 
antibodies 
Optimize antibody 
concentration, duration of 
washing and staining steps 
 1 
Table 2 ANTIBODY LIST 2 
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Target 
antigen  Supplier Cat No. 
Cell 
Type Analyses 
Fluorophore 
type Clone Buffer Concentration Dilution 
SOX17 R&D 
 AF192
4 
Endod
erm IF 
Unconjugate
d 
Polycl
onal 
Donkey  
Serum (DS) 200 µg/ml  1:100 
GATA4 Santa Cruz  
sc-
25310 FP FC 
Unconjugate
d  G-4 DS 200 µg/ml  1:100 
HNF4A Santa Cruz 
 sc-
8987 HB IF 
Unconjugate
d  H-171 DS 200 µg/ml  1:100  
AFP Dako  A-008 HB IF/FC  
Unconjugate
d 
Polycl
onal DS  344 000 IU/mL 1:100  
TBX3 Santa Cruz 
 sc-
17871 HB IF 
Unconjugate
d A-20 DS 200 µg/ml  1:100 
SOX9  Santa Cruz 
sc-
20095  
CP/CL
Cs IF/FC  
Unconjugate
d  H-90  DS 200 µg/ml  1:100  
CK7 Abcam 
 ab684
59 CLC IF/FC 
Unconjugate
d  
EPR16
19Y DS  0.111 mg/ml 1:100 
CK7 Abcam ab9021 CLC IF/FC 
Unconjugate
d 
RCK1
05 DS 1 mg/ml 1:100 
NANOG R&D AF1997 hPSCs IF/FC  
Unconjugate
d  
Polycl
onal  DS  200 µg/ml  1:100 
Oct3-4 Santa Cruz  
 sc-
9081 hPSCs IF/FC 
Unconjugate
d H-134 DS 200 µg/ml  1:100  
CK19 Abcam 
 ab775
4 CLC IF/ FC 
Unconjugate
d 
A53-
B/A2 DS  1 mg/ml 1:100 
TBR2/ 
EOMES Abcam 
ab2334
5  DE  IF/FC 
Unconjugate
d  
Polycl
onal DS 200 µg/ml  1:100 
FOXA2 R&D AF2400 FP FC 
Unconjugate
d  
Polycl
onal DS 200 µg/ml  1:100 
 1 
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Figure legends 1 
Figure 1 Generation of Cholangiocyte-like Cells (CLCs) from human 2 
Pluripotent Stem Cells (hPSCs). (a) Schematic representation of the protocol 3 
for the generation of hPSC-derived CLCs. DE: Definitive Endoderm, FP: 4 
Foregut progenitors, HB: Hepatoblasts, CP: Cholangiocyte Progenitors; BMP, 5 
bone morphogenetic protein; Ly294002 is a phosphatidylinositol-3-OH kinase 6 
inhibitor; CDM, chemically defined medium; RPMI, Roswell Park Memorial 7 
Institute medium; SB, SB-431542; HGF, hepatocyte growth factor; RA, 8 
retinoic acid; EGF, epidermal growth factor; FGF, fibroblast growth factor. 9 
Schematic modified from 7. The procedure steps corresponding to each stage 10 
are noted for reference. (b) Light microscopy images of cells at key stages of 11 
CLC differentiation. Scale bars for hPSCs, DE, FPs, CPs: 500 μm; HBs: 100 12 
μm; zoomed in images: 50μm. The procedure steps and day numbers 13 
corresponding to each image are noted for reference. 14 
 15 
Figure 2 Derivation of CLCs from embryonic stem (ES) cells. IF analyses 16 
demonstrating the expression of key biliary markers (CK7, CK19) in a CLC 17 
organoid generated from ES cells (H9). Scale bars: 100 μm. See table 2 for a 18 
detailed list of the antibodies and concentrations used. 19 
  20 
Figure 3 Immunofluorescence analyses demonstrating the expression of 21 
characteristic markers at key stages of CLC differentiation. Scale bars: 100 22 
μm. See table 2 for a detailed list of the antibodies and concentrations used 23 
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The method for staining CLC organoids is described in procedure steps 28-1 
39. 2 
 3 
Figure 4 Flow cytometry analyses demonstrating the expression of 4 
characteristic markers at key stages of CLC differentiation. CLC organoids 5 
were harvested as described in procedure steps 40-47. Cells were 6 
dissociated into single cells following incubation with TrypLE for 5 minutes at 7 
37oC and fixed with 4% PFA for 20 minutes at 4oC. The cells were stained for 8 
IF as previously described7, using the antibodies provided in table 2. A 9 
standard gating strategy was used25 demonstrated in Supplementary Fig 2.  A 10 
minimum of 2x104 gated events were used for analysis. Post sort fractions are 11 
indicated in the quadrants of each graph. The average differentiation 12 
efficiency from hPSCs to CLCs across three lines (CK7+/Sox9+ organoids) 13 
was 77% (s.d. = 6.5%)7. 14 
 15 
Figure 5 Functional properties of CLC organoids. (a) CLC organoids 16 
demonstrating characteristic ALP staining. Mouse embryonic feeders are 17 
used as a negative control. Scale bars: 100 μm. (b) GGT activity of CLC 18 
organoids measured in absorbance units (AU); n=3; Mouse Embryonic 19 
Feeders (MEFs) are used as a negative control. Error bars, standard 20 
deviation; individual data points are demonstrated; *P<0.05, two tailed 21 
student’s t-test; F-test used to compare variances, P=0.1218 (no significant 22 
difference in variance). GGT and ALP activity were assessed using 23 
commercially available kits (MaxDiscovery™ gamma-Glutamyl Transferase 24 
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(GGT) Enzymatic Assay Kit and BCIP/NBT Color Development Substrate 1 
respectively) according to the manufacturer’s instructions. 2 
 3 
Supplementary Figure legends 4 
Supplementary Figure 1 5 
Morphology of CLC organoids. CLC organoids exhibit a typical cystic or 6 
branching tubular morphology. The black arrow indicates a tubular organoid, 7 
while the white arrow indicates a branching point. Scale bars: 100μm 8 
 9 
Supplementary Figure 2 10 
Gating strategy used for the flow cytometry analyses demonstrated in Figure 11 
4. Viable cells were gated based on forward scatter and side scatter and 12 
single cells were then gated based of forward scatter and pulse width. 2ary 13 
only controls were used to set the threshold for the FITC and APC channels. 14 
 15 
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